CHICAGO — Rosnilimab, a novel pathogenic T-cell depleting drug, met its primary endpoint of changes in DAS28 C-reactive ...

Administration of opioid medications to people who present to the ED with acute sickle cell disease pain often does not happen as quickly as guidelines recommend, data presented at ASH Annual Meeting ...

North London Council announces part a partnership with telecoms infrastructure operator to deploy small cell technology ...

Aradigm Health, a new benefits platform aimed at easing the financial sting of coverage for cell and gene therapies, has ...

A foundation enrolls 100 sickle cell patients in Nigeria's NHIS to ease the financial burden of treatment and urges more ...

The first patients in the world have been treated with Scarcell Therapeutics' aGF Therapy using gum cells designed to relieve ...

Patients with <7/8 transplants had a 1-year survival of 85.6% versus 78.6% for those who received better-matched donor cells.

Research presented at the 2025 ASH Annual Meeting sheds light on serious side effects that appear weeks or months after CAR T cell therapy for multiple myeloma.

Cellarity presented new preclinical data on investigational programs for sickle cell disease and myelofibrosis during the ASH Annual Meeting.

A new tool developed by Helmholtz Munich and the German Center for Diabetes Research and the University of Bonn makes spatial ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, ...

Kylie Jenner is opening up about undergoing stem cell therapy after experiencing “chronic back pain” for almost three years.